Pro-Gly-Pro comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
=== 21st century === As of 2014, there were more than 11,000 of these institutions worldwide. Many of the more established think tanks, created during the Cold War, are focused on international affairs, security studies, and foreign policy. The median think tank publishes 138 articles a year, albeit there is substantial variation, with the Brookings Institution having published 3,880 reports in 2020 alone. Other prolific publishers include the Wilson Center or the CSIS.
The military responded with force and in the ensuing crossfire some 120 people lost their lives, including most of the guerrillas (several high-ranking operatives among them) and 12 Supreme Court Judges.[1] Both sides blamed each other for the bloodbath, which marked the end of Betancur's peace process.[2] Meanwhile, individual FARC members initially joined the UP leadership in representation of the guerrilla command, though most of the guerrilla's chiefs and militiamen did not demobilize nor disarm, as that was not a requirement of the process at that point in time. Tension soon significantly increased, as both sides began to accuse each other of not respecting the cease-fire. According to historian Daniel Pecáut, the creation of the Patriotic Union took the guerrillas' political message to a wider public outside of the traditional communist spheres of influence and led to local electoral victories in regions such as Urabá and Antioquia, with their mayoral candidates winning 23 municipalities and their congressional candidates gaining 14 seats (five in the Senate, nine in the lower Chamber) in 1988. Pecáut stated that new recruits entered the guerrilla army and its urban militia units during this period, and that the FARC continued to carry out kidnappings and target regional politicians for assassination.
On 20 October 2005, Hoffmann-La Roche decided to license other companies to manufacture Oseltamivir. Also in 2005, Roche acquired the Swiss company GlycArt Biotechnology in order to acquire technology to afucosylate antibodies; one of its products in development was obinutuzumab, which gained FDA approval in November 2013 for the treatment of chronic lymphocytic leukemia. On 22 January 2008, Roche acquired Ventana Medical Systems for $3.4 billion. On 2 January 2009, Roche acquired Memory Pharmaceuticals Corp. On 26 March 2009, Roche acquired Genentech for $46.8 billion. On 12 March 2009, Roche agreed to fully acquire Genentech, in which it had held a majority stake since 1990, after eight months of negotiations. As a result of the Genentech acquisition, Roche moved its Palo Alto–based research facilities to its campus that straddles the border between Clifton, New Jersey and Nutley, New Jersey while Roche's United States headquarters, located on the New Jersey site since 1929, was moved to Genentech's facility in South San Francisco. Genentech became a wholly owned subsidiary group of Roche on 25 March 2009. Roche began vacating the NJ site in 2012, and sold it off in 2016. Roche acquired Medingo Ltd. in April 2010, for $160 million and BioImagene, Inc. in August for $100 million. In 2011, the company received the International Society for Pharmaceutical Engineering Facility of the Year Award for Process Innovation for Roche's "MyDose" Clinical Supply project. In March 2011, Roche acquired PVT Probenverteiltechnik GmbH for up to €85 million.
=== mzPeak === Due to the increasing size of mass spectrometry raw-data files, the XML-backed mzML specification does not perform well enough with compressed data. The mzPeak format solves that by saving multiple files in an uncompressed zip file, with the raw data stored in parquet files for fast random access. The structure of the format is heavily inspired by mzML. Its specification is under development, as of September 2026, by HUPO-PSI and interested parties.
Sources: en.wikipedia.org
=== June === June 1 A firefighter is killed and another injured in a shooting at a Los Angeles County Fire Department station in Santa Clarita. A special election is held in New Mexico to fill a vacancy in its 1st congressional district left by Deb Haaland when she resigned to become President Biden's Secretary of the Interior. Democrat Melanie Stansbury wins with 79,837 of the 132,262 votes cast (60.36%). COVID-19 pandemic SARS-CoV-2 Delta variant becomes the dominant strain of COVID-19 in the United States. COVID-19 vaccines – Moderna seeks full approval from the FDA for the Moderna COVID-19 vaccine. Michigan lifts several face mask requirements at outdoor gatherings and loosens them at indoor gatherings and businesses. Fully vaccinated people are allowed to not wear masks in public, but unvaccinated and partially vaccinated people are still required to do so. June 2 – Paul Allard Hodgkins, a Tampa man who was seen in the U.S. Senate chamber during the January 6 riot at the United States Capitol, pleads guilty, making him the second suspect to do so after Jon Schaffer. June 3 – The FBI announces that it has opened an investigation into Postmaster General Louis DeJoy over campaign fundraising. June 4 Facebook's Oversight Board announces its ban on former President Donald Trump's personal account will last until January 2023. Trump was originally banned for posting a message supporting the January 6 insurrectionists.
Over-expression of human wild-type or A53T-mutant alpha-synuclein in primates drives deposition of alpha-synuclein in the ventral midbrain, degeneration of the dopaminergic system and impaired motor performance. Although the accumulation and aggregation of alpha-synuclein in most Parkinson's disease patients primarily result from posttranscriptional mechanisms, targeting its production remains a potential therapeutic approach. Research indicates that microRNA-7 and the naturally occurring small molecule quercetin can reduce alpha-synuclein levels under experimental conditions. Certain sections of the alpha-synuclein protein may play a role in the tauopathies. In children with autism spectrum disorders, the serum levels of alpha-synuclein have been reported to be significantly higher. A correlation to higher levels of e.coli and pro-inflammatory gut microbiome in those patients and an approach through disease modifying polysaccharides has been reported in clinical pilot studies. A prion form of the protein alpha-synuclein may be a causal agent for the disease multiple system atrophy.
As a result, the royalist cause began to collapse in the Americas. Over the course of the next decade, the Patriots' armies won major victories and obtained independence in their respective countries. Spain did not change the position against separatism, but the political instability in Spain, without a navy, army or treasury, convinced many Spanish Americans of the need to formally establish independence from the metropole. In Spain, a French army of the Holy Alliance invaded and supported the absolutists, restored Ferdinand VII, and occupied Spain until 1828.
The atomic radii of the alkali metals increase going down the group. Because of the shielding effect, when an atom has more than one electron shell, each electron feels electric repulsion from the other electrons as well as electric attraction from the nucleus. In the alkali metals, the outermost electron only feels a net charge of +1, as some of the nuclear charge (which is equal to the atomic number) is cancelled by the inner electrons; the number of inner electrons of an alkali metal is always one less than the nuclear charge. Therefore, the only factor which affects the atomic radius of the alkali metals is the number of electron shells. Since this number increases down the group, the atomic radius must also increase down the group. The ionic radii of the alkali metals are much smaller than their atomic radii. This is because the outermost electron of the alkali metals is in a different electron shell than the inner electrons, and thus when it is removed the resulting atom has one fewer electron shell and is smaller. Additionally, the effective nuclear charge has increased, and thus the electrons are attracted more strongly towards the nucleus and the ionic radius decreases.
The clinical manifestations present at birth are generalized hypotonia, muscle weakness, developmental delay with intellectual disability and occasional seizures. The congenital muscular dystrophy is characterized by hypoglycosylation of α-dystroglycan. Those born with the disease also experience severe ocular and brain defects. Half of all children with WWS are born with encephalocele, which is a gap in the skull that will not seal. The meninges of the brain protrude through this gap due to the neural tube failing to close during development. A malformation of the a baby's cerebellum is often a sign of this disease. Common ocular issues associated with WWS are abnormally small eyes and retinal abnormalities cause by an underdeveloped light-sensitive area in the back of the eye.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.